Literature DB >> 30049378

Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.

J Kevin Hicks1, Theresa Boyle2, Lee A Albacker3, Russell Madison3, Garrett Frampton3, Benjamin C Creelan4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30049378     DOI： 10.1016/j.jtho.2018.03.028

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Structural basis for RNA surveillance by the human nuclear exosome targeting (NEXT) complex.

Authors:  M Rhyan Puno; Christopher D Lima
Journal:  Cell       Date:  2022-06-09       Impact factor: 66.850

2.  A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma.

Authors:  Shaowei Lan; Hui Li; Ying Liu; Jinhua Xu; Zhicheng Huang; Shi Yan; Qiang Zhang; Ying Cheng
Journal:  Onco Targets Ther       Date:  2020-11-10       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.